Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab175578-100μg
|
100μg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$189.90
|
|
|
Ab175578-1mg
|
1mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$919.90
|
|
|
Ab175578-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$2,299.90
|
|
|
Ab175578-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$3,679.90
|
|
Purity≥90% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Conjugated (MC-VC-PAB-MMAE)
| Product Name | Lifastuzumab vedotin (anti-SLC34A2) - Primary antibody, specific to SLC34A2, Human IgG1, Antibody of Sodium phosphate 2 |
|---|---|
| Synonyms | Na(+)-dependent phosphate cotransporter 2B antibody | Na(+)/Pi cotransporter 2B antibody | NaPi-2b antibody | NaPi3b antibody | NPT2B_HUMAN antibody | SLC34A2 antibody | Sodium-dependent phosphate transport protein 2B antibody | Sodium-phosphate transport |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥90%(SDS-PAGE&SEC-HPLC), See COA |
| Host species | Human |
| Specificity | SLC34A2 |
| Conjugation | MC-VC-PAB-MMAE |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | INHIBITOR |
| Mechanism of action | Antibody of Sodium phosphate 2 |
| Product Description |
Lifastuzumab vedotin (anti-SLC34A2) is an antibody-drug conjugate (ADC) composed of a humanized anti-NaPi2b monoclonal antibody and an anti-mitotic cytotoxic agent, monomethyl auristatin E (MMAE) . Lifastuzumab vedotin (anti-SLC34A2) is used in the treatment of platinum-resistant ovarian cancer. |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 145 kDa |
| Purification Method | Protein A purified |
| Shape | Liquid |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| CAS | 1401812-88-1 |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Lifastuzumab vedotin (anti-SLC34A2) (Ab175578) - Flow Cytometry
Flow Cytometry analysis of SK-OV-3 cells labelling SLC34A2 (red) with Lifastuzumab vedotin (anti-SLC34A2) (Ab175578). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Lifastuzumab vedotin (anti-SLC34A2) (Ab175578) - ELISA
Immobilized Recombinant Human SLC34A2-NhFc protein at 2.0 μg/mL can bind Lifastuzumab vedotin (anti-SLC34A2) (Ab175578) with the EC
₅₀
of 61.75 ng/mL.
Lifastuzumab vedotin (anti-SLC34A2) (Ab175578) - SEC
The purity of Lifastuzumab vedotin (anti-SLC34A2) (Ab175578) is more than 95% verified by HPLC.